1
|
Ward RD, Tran JS, Banta AB, Bacon EE, Rose WE, Peters JM. Essential gene knockdowns reveal genetic vulnerabilities and antibiotic sensitivities in Acinetobacter baumannii. mBio 2024; 15:e0205123. [PMID: 38126769 PMCID: PMC10865783 DOI: 10.1128/mbio.02051-23] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/01/2023] [Accepted: 11/20/2023] [Indexed: 12/23/2023] Open
Abstract
The emergence of multidrug-resistant Gram-negative bacteria underscores the need to define genetic vulnerabilities that can be therapeutically exploited. The Gram-negative pathogen, Acinetobacter baumannii, is considered an urgent threat due to its propensity to evade antibiotic treatments. Essential cellular processes are the target of existing antibiotics and a likely source of new vulnerabilities. Although A. baumannii essential genes have been identified by transposon sequencing, they have not been prioritized by sensitivity to knockdown or antibiotics. Here, we take a systems biology approach to comprehensively characterize A. baumannii essential genes using CRISPR interference (CRISPRi). We show that certain essential genes and pathways are acutely sensitive to knockdown, providing a set of vulnerable targets for future therapeutic investigation. Screening our CRISPRi library against last-resort antibiotics uncovered genes and pathways that modulate beta-lactam sensitivity, an unexpected link between NADH dehydrogenase activity and growth inhibition by polymyxins, and anticorrelated phenotypes that may explain synergy between polymyxins and rifamycins. Our study demonstrates the power of systematic genetic approaches to identify vulnerabilities in Gram-negative pathogens and uncovers antibiotic-essential gene interactions that better inform combination therapies.IMPORTANCEAcinetobacter baumannii is a hospital-acquired pathogen that is resistant to many common antibiotic treatments. To combat resistant A. baumannii infections, we need to identify promising therapeutic targets and effective antibiotic combinations. In this study, we comprehensively characterize the genes and pathways that are critical for A. baumannii viability. We show that genes involved in aerobic metabolism are central to A. baumannii physiology and may represent appealing drug targets. We also find antibiotic-gene interactions that may impact the efficacy of carbapenems, rifamycins, and polymyxins, providing a new window into how these antibiotics function in mono- and combination therapies. Our studies offer a useful approach for characterizing interactions between drugs and essential genes in pathogens to inform future therapies.
Collapse
Affiliation(s)
- Ryan D. Ward
- Pharmaceutical Sciences Division, School of Pharmacy, University of Wisconsin-Madison, Madison, Wisconsin, USA
- Laboratory of Genetics, University of Wisconsin-Madison, Madison, Wisconsin, USA
| | - Jennifer S. Tran
- Pharmaceutical Sciences Division, School of Pharmacy, University of Wisconsin-Madison, Madison, Wisconsin, USA
- Microbiology Doctoral Training Program, University of Wisconsin-Madison, Madison, Wisconsin, USA
| | - Amy B. Banta
- Pharmaceutical Sciences Division, School of Pharmacy, University of Wisconsin-Madison, Madison, Wisconsin, USA
- Great Lakes Bioenergy Research Center, University of Wisconsin-Madison, Madison, Wisconsin, USA
| | - Emily E. Bacon
- Pharmaceutical Sciences Division, School of Pharmacy, University of Wisconsin-Madison, Madison, Wisconsin, USA
- Microbiology Doctoral Training Program, University of Wisconsin-Madison, Madison, Wisconsin, USA
| | - Warren E. Rose
- Pharmacy Practice Division, School of Pharmacy, University of Wisconsin-Madison, Madison, Wisconsin, USA
| | - Jason M. Peters
- Pharmaceutical Sciences Division, School of Pharmacy, University of Wisconsin-Madison, Madison, Wisconsin, USA
- Great Lakes Bioenergy Research Center, University of Wisconsin-Madison, Madison, Wisconsin, USA
- Department of Bacteriology, University of Wisconsin-Madison, Madison, Wisconsin, USA
- Department of Medical Microbiology and Immunology, University of Wisconsin-Madison, Madison, Wisconsin, USA
- Center for Genomic Science Innovation, University of Wisconsin-Madison, Madison, Wisconsin, USA
| |
Collapse
|
2
|
Ward RD, Tran JS, Banta AB, Bacon EE, Rose WE, Peters JM. Essential Gene Knockdowns Reveal Genetic Vulnerabilities and Antibiotic Sensitivities in Acinetobacter baumannii. BIORXIV : THE PREPRINT SERVER FOR BIOLOGY 2023:2023.08.02.551708. [PMID: 37577569 PMCID: PMC10418195 DOI: 10.1101/2023.08.02.551708] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 08/15/2023]
Abstract
The emergence of multidrug-resistant Gram-negative bacteria underscores the need to define genetic vulnerabilities that can be therapeutically exploited. The Gram-negative pathogen, Acinetobacter baumannii, is considered an urgent threat due to its propensity to evade antibiotic treatments. Essential cellular processes are the target of existing antibiotics and a likely source of new vulnerabilities. Although A. baumannii essential genes have been identified by transposon sequencing (Tn-seq), they have not been prioritized by sensitivity to knockdown or antibiotics. Here, we take a systems biology approach to comprehensively characterize A. baumannii essential genes using CRISPR interference (CRISPRi). We show that certain essential genes and pathways are acutely sensitive to knockdown, providing a set of vulnerable targets for future therapeutic investigation. Screening our CRISPRi library against last-resort antibiotics uncovered genes and pathways that modulate beta-lactam sensitivity, an unexpected link between NADH dehydrogenase activity and growth inhibition by polymyxins, and anticorrelated phenotypes that underpin synergy between polymyxins and rifamycins. Our study demonstrates the power of systematic genetic approaches to identify vulnerabilities in Gram-negative pathogens and uncovers antibiotic-essential gene interactions that better inform combination therapies.
Collapse
Affiliation(s)
- Ryan D Ward
- Pharmaceutical Sciences Division, School of Pharmacy, University of Wisconsin-Madison, Madison, WI 53705
- Laboratory of Genetics, University of Wisconsin-Madison, Madison, WI 53706
| | - Jennifer S Tran
- Pharmaceutical Sciences Division, School of Pharmacy, University of Wisconsin-Madison, Madison, WI 53705
- Microbiology Doctoral Training Program, University of Wisconsin-Madison, Madison, WI 53706
| | - Amy B Banta
- Pharmaceutical Sciences Division, School of Pharmacy, University of Wisconsin-Madison, Madison, WI 53705
- Great Lakes Bioenergy Research Center, University of Wisconsin-Madison, Madison, WI 53726
| | - Emily E Bacon
- Pharmaceutical Sciences Division, School of Pharmacy, University of Wisconsin-Madison, Madison, WI 53705
- Microbiology Doctoral Training Program, University of Wisconsin-Madison, Madison, WI 53706
| | - Warren E Rose
- Pharmacy Practice Division, School of Pharmacy, University of Wisconsin-Madison, Madison, WI 53705
| | - Jason M Peters
- Pharmaceutical Sciences Division, School of Pharmacy, University of Wisconsin-Madison, Madison, WI 53705
- Great Lakes Bioenergy Research Center, University of Wisconsin-Madison, Madison, WI 53726
- Department of Bacteriology, University of Wisconsin-Madison, Madison, WI 53706
- Department of Medical Microbiology and Immunology, University of Wisconsin-Madison, Madison, WI 53706
- Center for Genomic Science Innovation, University of Wisconsin-Madison, Madison, WI 53706
| |
Collapse
|
3
|
Sharma M, Dhagat P, Kumar A. Delayed Cerebral abscess following a retained shrapnel. Med J Armed Forces India 2023; 79:117-120. [PMID: 36605354 PMCID: PMC9807653 DOI: 10.1016/j.mjafi.2020.12.024] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/15/2020] [Accepted: 12/26/2020] [Indexed: 02/01/2023] Open
Abstract
Retained foreign bodies following penetrating brain injuries continue to pose therapeutic dilemmas. Previously used aggressive approach involving extensive wound debridement and removal of foreign bodies caused additional neurological deficit with higher mortality. Less aggressive approach used more recently involving decompressive craniectomy has lead to higher incidence of retained foreign bodies with potential of infective sequelae. We describe one such case where, in presence of a retained foreign body, an intracranial abscess formed after a gap of 17 yrs. The case has peculiar radiological and morphological findings.
Collapse
Affiliation(s)
- Manish Sharma
- Senior Adviser (Surgery & Neurosurgery), Army Hospital (R&R), Delhi Cantt, India
| | - P.K. Dhagat
- Brig/i/c Adm, Command Hospital (Northern Command), Udhampur, India
| | - Anil Kumar
- Senior Adviser (Surgery & Neurosurgery), Command Hospital (Northern Command), Udhampur, India
| |
Collapse
|
4
|
Wesseling CMJ, Slingerland CJ, Veraar S, Lok S, Martin NI. Structure-Activity Studies with Bis-Amidines That Potentiate Gram-Positive Specific Antibiotics against Gram-Negative Pathogens. ACS Infect Dis 2021; 7:3314-3335. [PMID: 34766746 PMCID: PMC8669655 DOI: 10.1021/acsinfecdis.1c00466] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
![]()
Pentamidine, an FDA-approved
antiparasitic drug, was recently identified
as an outer membrane disrupting synergist that potentiates erythromycin,
rifampicin, and novobiocin against Gram-negative bacteria. The same
study also described a preliminary structure–activity relationship
using commercially available pentamidine analogues. We here report
the design, synthesis, and evaluation of a broader panel of bis-amidines
inspired by pentamidine. The present study both validates the previously
observed synergistic activity reported for pentamidine, while further
assessing the capacity for structurally similar bis-amidines to also
potentiate Gram-positive specific antibiotics against Gram-negative
pathogens. Among the bis-amidines prepared, a number of them were
found to exhibit synergistic activity greater than pentamidine. These
synergists were shown to effectively potentiate the activity of Gram-positive
specific antibiotics against multiple Gram-negative pathogens such
as Acinetobacter baumannii, Klebsiella pneumoniae, Pseudomonas
aeruginosa, and Escherichia coli, including polymyxin- and carbapenem-resistant strains.
Collapse
Affiliation(s)
- Charlotte M. J. Wesseling
- Biological Chemistry Group, Institute of Biology Leiden, Leiden University, 2333 BE Leiden, The Netherlands
| | - Cornelis J. Slingerland
- Biological Chemistry Group, Institute of Biology Leiden, Leiden University, 2333 BE Leiden, The Netherlands
| | - Shanice Veraar
- Biological Chemistry Group, Institute of Biology Leiden, Leiden University, 2333 BE Leiden, The Netherlands
| | - Samantha Lok
- Biological Chemistry Group, Institute of Biology Leiden, Leiden University, 2333 BE Leiden, The Netherlands
| | - Nathaniel I. Martin
- Biological Chemistry Group, Institute of Biology Leiden, Leiden University, 2333 BE Leiden, The Netherlands
| |
Collapse
|
5
|
Kan T, Komiya K, Yamasue M, Itai M, Tanaka A, Takeno Y, Takikawa S, Hiramatsu K, Kadota JI. Comparison of chest computed tomography features between pulmonary tuberculosis patients with culture-positive and culture-negative sputum for non-mycobacteria: A retrospective observational study. Medicine (Baltimore) 2021; 100:e26897. [PMID: 34397866 PMCID: PMC8341271 DOI: 10.1097/md.0000000000026897] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/26/2021] [Accepted: 07/17/2021] [Indexed: 01/04/2023] Open
Abstract
Although complication with non-mycobacterial pneumonia among patients with pulmonary tuberculosis (TB) may lead to poor prognosis, discrimination between TB complicated with and without non-mycobacterial pneumonia using radiological imaging has not been fully elucidated. We aimed to clarify the differences in chest computed tomography (CT) features between pulmonary TB patients with culture-positive and culture-negative sputum for non-mycobacteria.We retrospectively included consecutive patients admitted to our hospital from January 2013 to December 2015 for bacteriologically-confirmed pulmonary TB, who were tested by sputum culture for non-mycobacteria, and who underwent chest CT within 2 weeks before or after admission. Chest CT features were compared between pulmonary TB patients who had positive non-mycobacterial cultures and in those who had not.Of 202 patients with pulmonary TB, 186 (92%) were tested by sputum culture for non-mycobacteria and underwent chest CT. Among these, non-mycobacteria were isolated in 118 patients (63%), while 68 patients (37%) had negative cultures. Patients with a positive culture for non-mycobacteria were significantly older and had lower levels of physical activity and albumin, higher levels of C-reactive protein, and a greater number of respiratory failures. By CT, emphysematous lesions, ground-glass opacities, airspace consolidation, air-bronchogram, interlobular septal thickening, bronchiectasis, pleural effusion, pleural thickening, and lymph node enlargement were more frequently in patients with a positive culture for non-mycobacteria. These chest CT features could be helpful for detecting complication with non-mycobacterial pneumonia in patients with pulmonary TB.
Collapse
Affiliation(s)
- Takamasa Kan
- Department of Respiratory Medicine and Infectious Diseases, Oita University Faculty of Medicine, 1-1 Idaigaoka, Hasama-machi, Yufu, Oita, Japan
| | - Kosaku Komiya
- Department of Respiratory Medicine and Infectious Diseases, Oita University Faculty of Medicine, 1-1 Idaigaoka, Hasama-machi, Yufu, Oita, Japan
- Department of Internal Medicine, National Hospital Organization Nishi-Beppu Hospital, 4548 Tsurumi, Beppu, Oita, Japan
| | - Mari Yamasue
- Department of Respiratory Medicine and Infectious Diseases, Oita University Faculty of Medicine, 1-1 Idaigaoka, Hasama-machi, Yufu, Oita, Japan
- Department of Internal Medicine, National Hospital Organization Nishi-Beppu Hospital, 4548 Tsurumi, Beppu, Oita, Japan
| | - Mariko Itai
- Department of Internal Medicine, National Hospital Organization Nishi-Beppu Hospital, 4548 Tsurumi, Beppu, Oita, Japan
| | - Ai Tanaka
- Department of Respiratory Medicine and Infectious Diseases, Oita University Faculty of Medicine, 1-1 Idaigaoka, Hasama-machi, Yufu, Oita, Japan
| | - Yukiko Takeno
- Department of Respiratory Medicine and Infectious Diseases, Oita University Faculty of Medicine, 1-1 Idaigaoka, Hasama-machi, Yufu, Oita, Japan
- Department of Internal Medicine, National Hospital Organization Nishi-Beppu Hospital, 4548 Tsurumi, Beppu, Oita, Japan
| | - Shuichi Takikawa
- Department of Internal Medicine, National Hospital Organization Nishi-Beppu Hospital, 4548 Tsurumi, Beppu, Oita, Japan
| | - Kazufumi Hiramatsu
- Department of Respiratory Medicine and Infectious Diseases, Oita University Faculty of Medicine, 1-1 Idaigaoka, Hasama-machi, Yufu, Oita, Japan
| | - Jun-ichi Kadota
- Department of Respiratory Medicine and Infectious Diseases, Oita University Faculty of Medicine, 1-1 Idaigaoka, Hasama-machi, Yufu, Oita, Japan
| |
Collapse
|
6
|
Cetuk H, Anishkin A, Scott AJ, Rempe SB, Ernst RK, Sukharev S. Partitioning of Seven Different Classes of Antibiotics into LPS Monolayers Supports Three Different Permeation Mechanisms through the Outer Bacterial Membrane. LANGMUIR : THE ACS JOURNAL OF SURFACES AND COLLOIDS 2021; 37:1372-1385. [PMID: 33449700 DOI: 10.1021/acs.langmuir.0c02652] [Citation(s) in RCA: 15] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/12/2023]
Abstract
The outer membrane (OM) of Gram-negative (G-) bacteria presents a barrier for many classes of antibacterial agents. Lipopolysaccharide (LPS), present in the outer leaflet of the OM, is stabilized by divalent cations and is considered to be the major impediment for antibacterial agent permeation. However, the actual affinities of major antibiotic classes toward LPS have not yet been determined. In the present work, we use Langmuir monolayers formed from E. coli Re and Rd types of LPS to record pressure-area isotherms in the presence of antimicrobial agents. Our observations suggest three general types of interactions. First, some antimicrobials demonstrated no measurable interactions with LPS. This lack of interaction in the case of cefsulodin, a third-generation cephalosporin antibiotic, correlates with its low efficacy against G- bacteria. Ampicillin and ciprofloxacin also show no interactions with LPS, but in contrast to cefsulodin, both exhibit good efficacy against G- bacteria, indicating permeation through common porins. Second, we observe substantial intercalation of the more hydrophobic antibiotics, novobiocin, rifampicin, azithromycin, and telithromycin, into relaxed LPS monolayers. These largely repartition back to the subphase with monolayer compression. We find that the hydrophobic area, charge, and dipole all show correlations with both the mole fraction of antibiotic retained in the monolayer at the monolayer-bilayer equivalence pressure and the efficacies of these antibiotics against G- bacteria. Third, amine-rich gentamicin and the cationic antimicrobial peptides polymyxin B and colistin show no hydrophobic insertion but are instead strongly driven into the polar LPS layer by electrostatic interactions in a pressure-independent manner. Their intercalation stably increases the area per molecule (by up to 20%), which indicates massive formation of defects in the LPS layer. These defects support a self-promoted permeation mechanism of these antibiotics through the OM, which explains the high efficacy and specificity of these antimicrobials against G- bacteria.
Collapse
Affiliation(s)
- Hannah Cetuk
- Biology Department, University of Maryland, College Park, Maryland 20742, United States
| | - Andriy Anishkin
- Biology Department, University of Maryland, College Park, Maryland 20742, United States
| | - Alison J Scott
- Department of Microbial Pathogenesis, University of Maryland, Baltimore, Baltimore Maryland 21201, United States
| | - Susan B Rempe
- Center for Chemical, Biological, Radiation, and Nuclear Defense and Energy Technology, Sandia National Laboratories, Albuquerque, New Mexico 87185, United States
| | - Robert K Ernst
- Department of Microbial Pathogenesis, University of Maryland, Baltimore, Baltimore Maryland 21201, United States
| | - Sergei Sukharev
- Biology Department, University of Maryland, College Park, Maryland 20742, United States
| |
Collapse
|
7
|
Synthesis and activity of BNF15 against drug-resistant Mycobacterium tuberculosis. Future Med Chem 2020; 13:251-267. [PMID: 33295787 DOI: 10.4155/fmc-2019-0154] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
Abstract
Aim: Tuberculosis is the leading cause of mortality among infectious diseases worldwide. Finding a new competent anti tubercular therapy is essential. Materials & methods: We screened thousands of compounds and evaluated their efficacy against Mycobacterium tuberculosis. Results: Initially, 2-nitronaphtho[2,3-b]benzofuran-6,11-dione was active against M. tuberculosis. Next, among 15 newly synthesized derivatives, BNF15 showed promising effect against all drug-sensitive and drug-resistant M. tuberculosis (MIC: 0.02-0.78 μg/ml). BNF15 effectively killed intracellular M. tuberculosis and nontuberculous mycobacteria. BNF15 exhibited a prolonged post antibiotic effect superior to isoniazid, streptomycin, and ethambutol and synergistic interaction with rifampicin. In acute oral toxicity test, BNF15 did not show toxic effect at a concentration up to 2000 mg/kg. Conclusion: These results highlight the perspective of BNF15 to treat drug-resistant M. tuberculosis.
Collapse
|
8
|
Novel Hemocompatible Imine Compounds as Alternatives for Antimicrobial Therapy in Pharmaceutical Application. Processes (Basel) 2020. [DOI: 10.3390/pr8111476] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022] Open
Abstract
The aim of this study was to synthesize, characterize, and evaluate neoteric imine compounds for antimicrobial activity and hemocompatibility. Four compounds were synthesized using 3-thiophene carboxaldehyde, ethanol, amine, and acetic acid. The compounds were characterized using nuclear magnetic resonance (NMR) spectroscopy, Fourier transform infrared (FTIR) spectroscopy, differential scanning calorimetry (DSC), and powder X-ray diffraction (PXRD). A solubility study was conducted with various solvents and surfactants at 40 °C. An in vitro antimicrobial assay was performed against bacterial and fungal strains to determine the zone of inhibition and minimum inhibitory concentrations. Finally, an in vitro hemolysis study was conducted using rat erythrocytes. The structure of the compounds was confirmed by NMR, FTIR corroborated their functional group attributes, DSC determined their enthalpies of fusion and fusion temperatures, and PXRD confirmed their crystalline nature. These compounds were water-insoluble but soluble in chloroform, with a maximum solubility of ~80 mg/mL. The antimicrobial assay suggested that two of the products exerted potent activities against C. albicans and several bacterial strains. Finally, hemolysis analysis excluded the possibility of hemolysis at the assessed concentrations. In conclusion, two of the novel imine compounds showed promise as antimicrobial agents to control local and systemic microbial infections in a suitable dosage form.
Collapse
|
9
|
Umumararungu T, Mukazayire MJ, Mpenda M, Mukanyangezi MF, Nkuranga JB, Mukiza J, Olawode EO. A review of recent advances in anti-tubercular drug development. Indian J Tuberc 2020; 67:539-559. [PMID: 33077057 DOI: 10.1016/j.ijtb.2020.07.017] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/02/2019] [Revised: 03/24/2020] [Accepted: 07/15/2020] [Indexed: 02/06/2023]
Abstract
Tuberculosis is a global threat but in particular affects people from developing countries. It is thought that nearly a third of the population of the world live with its causative bacteria in a dormant form. Although tuberculosis is a curable disease, the chances of cure become slim as the disease becomes multidrug-resistant and the situation gets even worse as the disease becomes extensively drug-resistant. After approximately 5 decades without any new TB drug in the pipeline, there has been some good news in the recent years with the discovery of new drugs such as bedaquiline and delamanid as well as the discovery of new classes of anti-tubercular drugs. Some old drugs such as clofazimine, linezolid and many others which were not previously indicated for tuberculosis have been also repurposed for tuberculosis and they are performing well.
Collapse
Affiliation(s)
- Théoneste Umumararungu
- Department of Pharmacy, School of Medicine and Pharmacy, College of Medicine and Health Sciences, University of Rwanda, Rwanda.
| | - Marie Jeanne Mukazayire
- Department of Pharmacy, School of Medicine and Pharmacy, College of Medicine and Health Sciences, University of Rwanda, Rwanda
| | - Matabishi Mpenda
- Department of Pharmacy, School of Medicine and Pharmacy, College of Medicine and Health Sciences, University of Rwanda, Rwanda
| | - Marie Françoise Mukanyangezi
- Department of Pharmacy, School of Medicine and Pharmacy, College of Medicine and Health Sciences, University of Rwanda, Rwanda
| | - Jean Bosco Nkuranga
- Department of Chemistry, School of Science, College of Science and Technology, University of Rwanda, Rwanda
| | - Janvier Mukiza
- Department of Mathematical Science and Physical Education, School of Education, College of Education, University of Rwanda, Rwanda
| | | |
Collapse
|
10
|
Affiliation(s)
- Stephen W. Zimmerman
- Medical School School of Pharmacy University of Wisconsin H4/510 Clinical Science Center 600 Highland Avenue Madison, Wisconsin 53792
| | - Curtis A. Johnson
- Medical School School of Pharmacy University of Wisconsin H4/510 Clinical Science Center 600 Highland Avenue Madison, Wisconsin 53792
| |
Collapse
|
11
|
Kan T, Komiya K, Honjo K, Uchida S, Goto A, Kawano H, Takikawa S, Yoshimatsu T, Kadota JI. Impact of additional antibiotics on in-hospital mortality in tuberculosis isolated general bacteria: A propensity score analysis. J Infect Chemother 2019; 25:714-719. [PMID: 30982726 DOI: 10.1016/j.jiac.2019.03.022] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/11/2019] [Revised: 03/02/2019] [Accepted: 03/22/2019] [Indexed: 01/30/2023]
Abstract
Whether or not additional antibiotics with anti-tuberculosis agents are required to treat bacterial co-infection with pulmonary tuberculosis is unclear. We aimed to assess the impact of additional antibiotics on mortality in pulmonary tuberculosis patients whose sputum cultures were positive for general bacteria as a surrogate definition of bacterial pneumonia. This study was a single-center retrospective cohort using a propensity score analysis. We included patients who were admitted for pulmonary tuberculosis and whose sputum cultures were positive for general bacteria. The mortality of patients who received additional antibiotics was analyzed after adjusting for other variables, including the propensity score predicting treatment with additional antibiotics. We assessed 68 and 55 tuberculosis patients treated with and without general antibiotics, respectively. Additional antibiotics tended to be administered to patients with a high level of C-reactive protein and neutrophil count, poor performance status, hypoxemia and hypoalbuminemia (C-statistics of area under receiver operating characteristic curve to the propensity score; 0.884, p < 0.001). In the multivariate analysis, advanced age and not the use of additional antibiotics was associated with in-hospital mortality. Additional antibiotics with anti-tuberculosis agents may not improve the prognosis of pulmonary tuberculosis patients whose sputum cultures were positive for general bacteria. Isolation of general bacteria does not equate to complication with bacterial pneumonia, so physicians should not administer general antibiotics to TB patients based solely on the results of sputum culture for general bacteria. A prospective study is needed to verify these results using a more accurate definition of pulmonary tuberculosis complicated with bacterial pneumonia.
Collapse
Affiliation(s)
- Takamasa Kan
- Internal Medicine, National Hospital Organization Nishi-Beppu Hospital, 4548 Tsurumi, Beppu, Oita, 874-0840, Japan; Respiratory Medicine and Infectious Diseases, Oita University Faculty of Medicine, 1-1 Idaigaoka, Hasama-machi, Yufu, Oita, 879-5593, Japan
| | - Kosaku Komiya
- Internal Medicine, National Hospital Organization Nishi-Beppu Hospital, 4548 Tsurumi, Beppu, Oita, 874-0840, Japan; Respiratory Medicine and Infectious Diseases, Oita University Faculty of Medicine, 1-1 Idaigaoka, Hasama-machi, Yufu, Oita, 879-5593, Japan.
| | - Kokoro Honjo
- Internal Medicine, National Hospital Organization Nishi-Beppu Hospital, 4548 Tsurumi, Beppu, Oita, 874-0840, Japan; Respiratory Medicine and Infectious Diseases, Oita University Faculty of Medicine, 1-1 Idaigaoka, Hasama-machi, Yufu, Oita, 879-5593, Japan
| | - Sonoe Uchida
- Internal Medicine, National Hospital Organization Nishi-Beppu Hospital, 4548 Tsurumi, Beppu, Oita, 874-0840, Japan; Respiratory Medicine and Infectious Diseases, Oita University Faculty of Medicine, 1-1 Idaigaoka, Hasama-machi, Yufu, Oita, 879-5593, Japan
| | - Akihiko Goto
- Internal Medicine, National Hospital Organization Nishi-Beppu Hospital, 4548 Tsurumi, Beppu, Oita, 874-0840, Japan; Respiratory Medicine and Infectious Diseases, Oita University Faculty of Medicine, 1-1 Idaigaoka, Hasama-machi, Yufu, Oita, 879-5593, Japan
| | - Hiroshi Kawano
- Internal Medicine, National Hospital Organization Nishi-Beppu Hospital, 4548 Tsurumi, Beppu, Oita, 874-0840, Japan
| | - Shuichi Takikawa
- Internal Medicine, National Hospital Organization Nishi-Beppu Hospital, 4548 Tsurumi, Beppu, Oita, 874-0840, Japan
| | - Tetsuyuki Yoshimatsu
- Internal Medicine, National Hospital Organization Nishi-Beppu Hospital, 4548 Tsurumi, Beppu, Oita, 874-0840, Japan
| | - Jun-Ichi Kadota
- Respiratory Medicine and Infectious Diseases, Oita University Faculty of Medicine, 1-1 Idaigaoka, Hasama-machi, Yufu, Oita, 879-5593, Japan
| |
Collapse
|
12
|
Houben RMGJ, Lalli M, Kranzer K, Menzies NA, Schumacher SG, Dowdy DW. What if They Don't Have Tuberculosis? The Consequences and Trade-offs Involved in False-positive Diagnoses of Tuberculosis. Clin Infect Dis 2019; 68:150-156. [PMID: 29982375 PMCID: PMC6293007 DOI: 10.1093/cid/ciy544] [Citation(s) in RCA: 16] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/24/2018] [Accepted: 06/28/2018] [Indexed: 12/23/2022] Open
Abstract
To find the millions of missed tuberculosis (TB) cases, national TB programs are under pressure to expand TB disease screening and to target populations with lower disease prevalence. Together with imperfect performance and application of existing diagnostic tools, including empirical diagnosis, broader screening risks placing individuals without TB on prolonged treatment. These false-positive diagnoses have profound consequences for TB patients and prevention efforts, yet are usually overlooked in policy decision making. In this article we describe the pathways to a false-positive TB diagnosis, including trade-offs involved in the development and application of diagnostic algorithms. We then consider the wide range of potential consequences for individuals, households, health systems, and reliability of surveillance data. Finally, we suggest practical steps that the TB community can take to reduce the frequency and potential harms of false-positive TB diagnosis and to more explicitly assess the trade-offs involved in the screening and diagnostic process.
Collapse
Affiliation(s)
- Rein M G J Houben
- Tuberculosis Modelling Group, Tuberculosis Centre and Centre for Mathematical Modelling of Infectious Diseases
- Infectious Disease Epidemiology Department, Faculty of Epidemiology and Public Health, London School of Hygiene and Tropical Medicine, United Kingdom
| | - Marek Lalli
- Tuberculosis Modelling Group, Tuberculosis Centre and Centre for Mathematical Modelling of Infectious Diseases
- Infectious Disease Epidemiology Department, Faculty of Epidemiology and Public Health, London School of Hygiene and Tropical Medicine, United Kingdom
| | - Katharina Kranzer
- Infectious Disease Epidemiology Department, Faculty of Epidemiology and Public Health, London School of Hygiene and Tropical Medicine, United Kingdom
- Research Centre Borstel, National and Supranational Reference Laboratory, Germany
| | - Nick A Menzies
- Department of Global Health and Population, Harvard T. H. Chan School of Public Health, Boston, Massachusetts
| | | | - David W Dowdy
- Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland
| |
Collapse
|
13
|
O'Toole RF, Gautam SS. The host microbiome and impact of tuberculosis chemotherapy. Tuberculosis (Edinb) 2018; 113:26-29. [PMID: 30514510 DOI: 10.1016/j.tube.2018.08.015] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/23/2018] [Revised: 08/28/2018] [Accepted: 08/30/2018] [Indexed: 01/15/2023]
Abstract
The treatment of Mycobacterium tuberculosis infection is often viewed in isolation from other human microbial symbionts. Understandably, the clinical priority is eliminating active or latent tuberculosis (TB) in patients. With the increasing resolution of molecular biology technologies, it is becoming apparent that antibiotic treatment can perturb the homeostasis of the host microbiome. For example, dysbiosis of the gut microbiota has been associated with an increased risk of the development of asthma, obesity and diabetes. Therefore, fundamental questions include: Does TB chemotherapy cause disruption of the human microbiome and adverse effects in patients; and are there signature taxa of dysbiosis following TB treatment. In this review, we examine recent research on the detection of changes in the microbiome during antibiotic administration and discuss specific findings that relate to the impact of anti-tubercular chemotherapy.
Collapse
Affiliation(s)
- Ronan F O'Toole
- School of Medicine, College of Health and Medicine, University of Tasmania, Hobart, Australia; Department of Clinical Microbiology, School of Medicine, Trinity College Dublin, Ireland.
| | - Sanjay S Gautam
- School of Medicine, College of Health and Medicine, University of Tasmania, Hobart, Australia
| |
Collapse
|
14
|
Chon JW, Kim YJ, Kim YJ, Jung JY, Bae D, Khan S, Seo KH, Sung K. Addition of Rifampicin to Bolton Broth to Inhibit Extended-Spectrum β-Lactamase-ProducingEscherichia colifor the Detection ofCampylobacter. J Food Sci 2017. [DOI: 10.1111/1750-3841.13761] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- Jung-Whan Chon
- Div. of Microbiology, Natl. Center for Toxicological Research; US Food and Drug Administration; Jefferson AR 72079 U.S.A
| | - Young-Ji Kim
- KU Center for One Health, College of Veterinary Medicine; Konkuk Univ.; Hwayang-dong Gwangjin-gu Seoul 05029 Republic of Korea
| | - Young-Jo Kim
- Ministry of Food and Drug Safety; Osong 28159 Republic of Korea
| | - Ji Young Jung
- Div. of Microbiology, Natl. Center for Toxicological Research; US Food and Drug Administration; Jefferson AR 72079 U.S.A
| | - Dongryeoul Bae
- Div. of Microbiology, Natl. Center for Toxicological Research; US Food and Drug Administration; Jefferson AR 72079 U.S.A
| | - Saeed Khan
- Div. of Microbiology, Natl. Center for Toxicological Research; US Food and Drug Administration; Jefferson AR 72079 U.S.A
| | - Kun-Ho Seo
- KU Center for One Health, College of Veterinary Medicine; Konkuk Univ.; Hwayang-dong Gwangjin-gu Seoul 05029 Republic of Korea
| | - Kidon Sung
- Div. of Microbiology, Natl. Center for Toxicological Research; US Food and Drug Administration; Jefferson AR 72079 U.S.A
| |
Collapse
|
15
|
Abstract
Rifamycins inhibit RNA polymerase of most bacterial genera. Rifampicin remains part of combination therapy for treating tuberculosis (TB), and for treating Gram-positive prosthetic joint and valve infections, in which biofilms are prominent. Rifabutin has use for AIDS patients in treating mycobacterial infections TB and Mycobacterium avium complex (MAC), having fewer drug-drug interactions that interfere with AIDS medications. Rifabutin is occasionally used in combination to eradicate Helicobacter pylori (peptic ulcer disease). Rifapentine has yet to fulfill its potential in reducing time of treatment for TB. Rifaximin is a monotherapeutic agent to treat gastrointestinal (GI) disorders, such as hepatic encephalopathy, irritable bowel syndrome, and travelers' diarrhea. Rifaximin is confined to the GI tract because it is not systemically absorbed on oral dosing, achieving high local concentrations, and showing anti-inflammatory properties in addition to its antibacterial activity. Resistance issues are unavoidable with all the rifamycins when the bioburden is high, because of mutations that modify RNA polymerase.
Collapse
|
16
|
Enrofloxacin and macrolides alone or in combination with rifampicin as antimicrobial treatment in a bovine model of acute Chlamydia psittaci infection. PLoS One 2015; 10:e0119736. [PMID: 25768665 PMCID: PMC4358964 DOI: 10.1371/journal.pone.0119736] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/24/2014] [Accepted: 01/15/2015] [Indexed: 12/26/2022] Open
Abstract
Chlamydia psittaci is a zoonotic bacterium with a wide host range that can cause respiratory disease in humans and cattle. In the present study, effects of treatment with macrolides and quinolones applied alone or in combination with rifampicin were tested in a previously established bovine model of respiratory C. psittaci infection. Fifty animals were inoculated intrabronchially at the age of 6-8 weeks. Seven served as untreated controls, the others were assigned to seven treatment groups: (i) rifampicin, (ii) enrofloxacin, (iii) enrofloxacin + rifampicin, (iv) azithromycin, (v) azithromycin + rifampicin, (vi) erythromycin, and (vii) erythromycin + rifampicin. Treatment started 30 hours after inoculation and continued until 14 days after inoculation (dpi), when all animals were necropsied. The infection was successful in all animals and sufficient antibiotic levels were detected in blood plasma and tissue of the treated animals. Reisolation of the pathogen was achieved more often from untreated animals than from other groups. Nevertheless, pathogen detection by PCR was possible to the same extent in all animals and there were no significant differences between treated and untreated animals in terms of local (i.e., cell count and differentiation of BALF-cells) and systemic inflammation (i.e. white blood cells and concentration of acute phase protein LBP), clinical signs, and pathological findings at necropsy. Regardless of the reduced reisolation rate in treated animals, the treatment of experimentally induced respiratory C. psittaci infection with enrofloxacin, azithromycin or erythromycin alone or in combination with rifampicin was without obvious benefit for the host, since no significant differences in clinical and pathological findings or inflammatory parameters were detected and all animals recovered clinically within two weeks.
Collapse
|
17
|
Prohl A, Lohr M, Ostermann C, Liebler-Tenorio E, Berndt A, Schroedl W, Rothe M, Schubert E, Sachse K, Reinhold P. Evaluation of antimicrobial treatment in a bovine model of acute Chlamydia psittaci infection: tetracycline versus tetracycline plus rifampicin. Pathog Dis 2015; 73:1-12. [PMID: 25113145 DOI: 10.1111/2049-632x.12212] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/19/2014] [Accepted: 08/05/2014] [Indexed: 01/18/2023] Open
Abstract
Antimicrobial treatment of chlamydial infections is known to be of limited efficacy. In this study, effects of doxycycline (D), usually the drug of choice, were compared with the combined therapy of doxycycline and rifampicin (R) in a bovine model of respiratory Chlamydia psittaci infection. After intrabronchial inoculation of the pathogen, 30 animals were assigned to five groups (n = 6 per group): untreated controls, monotherapy with D (5 mg kg(-1)day(-1) or 10 mg kg(-1)day(-1)), and combination therapy of D and R (600 mg day(-1)). Treatment continued until day 14 post inoculation (d.p.i.). Clinical signs, inflammatory markers, and pathological findings confirmed successful infection in all animals. Reisolation of the pathogen was possible in 4/6 untreated animals and in 4/12 animals treated with D alone until 4 d.p.i., but in none of the calves of the two D + R groups. Pathogen detection was possible in all animals without significant differences among groups. Severity of disease and time course of its resolution, assessed by clinical and pathological findings as well as inflammatory parameters, were not significantly different between untreated controls and calves receiving D alone or in combination with R. Regardless of the treatment regimen, all groups recovered clinically and cleared the infection within 2 weeks.
Collapse
Affiliation(s)
- Annette Prohl
- Institute of Molecular Pathogenesis at Friedrich-Loeffler-Institut (Federal Research Institute for Animal Health), Jena, Germany
| | - Markus Lohr
- Institute of Molecular Pathogenesis at Friedrich-Loeffler-Institut (Federal Research Institute for Animal Health), Jena, Germany
| | - Carola Ostermann
- Institute of Molecular Pathogenesis at Friedrich-Loeffler-Institut (Federal Research Institute for Animal Health), Jena, Germany
| | - Elisabeth Liebler-Tenorio
- Institute of Molecular Pathogenesis at Friedrich-Loeffler-Institut (Federal Research Institute for Animal Health), Jena, Germany
| | - Angela Berndt
- Institute of Molecular Pathogenesis at Friedrich-Loeffler-Institut (Federal Research Institute for Animal Health), Jena, Germany
| | - Wieland Schroedl
- Institute of Bacteriology and Mycology, Veterinary Faculty at The University of Leipzig, Leipzig, Jena, Germany
| | | | - Evelyn Schubert
- Institute of Molecular Pathogenesis at Friedrich-Loeffler-Institut (Federal Research Institute for Animal Health), Jena, Germany OIE Reference Laboratory for Chlamydiosis at Friedrich-Loeffler-Institut (Federal Research Institute for Animal Health), Jena, Germany
| | - Konrad Sachse
- Institute of Molecular Pathogenesis at Friedrich-Loeffler-Institut (Federal Research Institute for Animal Health), Jena, Germany OIE Reference Laboratory for Chlamydiosis at Friedrich-Loeffler-Institut (Federal Research Institute for Animal Health), Jena, Germany
| | - Petra Reinhold
- Institute of Molecular Pathogenesis at Friedrich-Loeffler-Institut (Federal Research Institute for Animal Health), Jena, Germany
| |
Collapse
|
18
|
Tascini C, Gemignani G, Ferranti S, Tagliaferri E, Leonildi A, Lucarini A, Menichetti F. Microbiological Activity and Clinical Efficacy of a Colistin and Rifampin Combination in Multidrug-ResistantPseudomonas aeruginosaInfections. J Chemother 2013; 16:282-7. [PMID: 15330326 DOI: 10.1179/joc.2004.16.3.282] [Citation(s) in RCA: 52] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/31/2022]
Abstract
The aim of the study was to assess the microbiological activity and clinical efficacy of colistin and rifampin combination against multidrug-resistant (MDR) Pseudomonas aeruginosa infections. The antimicrobial activity of the colistin/rifampin combination was evaluated using the checkerboard and time-kill curve methods against different MDR P. aeruginosa strains. The combination of rifampin and colistin resulted fully (1 strain) or partially (5 strains) synergistic for 6/7 strains and minimum inhibitory concentrations (MICs) in combination were reduced to easily obtainable therapeutic levels. The time-kill curves showed that the combination was bactericidal against the strains tested. The clinical efficacy of the combination was tested in four patients with difficult-to treat infections (sepsis or pneumonia) caused by MDR P. aeruginosa. All infections were successfully treated. Our microbiological and clinical observations suggest that the addition of rifampin to colistin may result in a synergistic bactericidal combination that may be useful in patients with infections caused by MDR P. aeruginosa which are difficult to cure.
Collapse
Affiliation(s)
- C Tascini
- Infectious Diseases Unit, Azienda Ospedaliera Pisana, Pisa, Italy.
| | | | | | | | | | | | | |
Collapse
|
19
|
Cakici O, Aksak S, Unal D, Sipal S, Keles S, Dumlu T, Karamese M. Effects of intraocular rifampicin on retinal ganglion cell structure: a stereological and histopathological study. Int J Ophthalmol 2013; 6:596-9. [PMID: 24195032 DOI: 10.3980/j.issn.2222-3959.2013.05.08] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/26/2012] [Accepted: 08/02/2013] [Indexed: 11/02/2022] Open
Abstract
AIM To determine the histopathological changes of rifampicin applied intravitreally on retinal ganglion cells by means of stereological and histopathological methods. METHODS For this study twenty-four New Zealand adult rabbits were divided into four groups (n=6 for each group). 50µg/0.1mL (group 1), 100µg/0.1mL (group 2), 150µg/0.1mL (group 3) and 200µg/0.1mL (group 4), rifampicin were injected into the vitreous of the right eyes of animals, their left eyes were used as control (group 5). After the 28(th) day of application, animals were anesthetised with xylazine (8mg/kg, IM) and then their eyes were enucleated immediately. Patterns were taken away and eyes were prepared for both stereological and electromicroscopic observation. RESULTS Depending on the high dose of rifampicin, some histopathological changes such as cytoplasmic dilatation and damaged membrane were observed on the electromicroscopic level. Using quantitative examination, which was done at the light microscopic level, it was shown that the number of neurons decreased linearly as rifampicin dose increased when compared with the control group. CONCLUSION Based on these findings, low-dose rifampicin (50µg/0.1mL) may be useful for treatment of the ocular diseases.
Collapse
Affiliation(s)
- Ozgür Cakici
- Department of Ophthalmology, Erzurum Research and Education Hospital, Erzurum 25100, Turkey
| | | | | | | | | | | | | |
Collapse
|
20
|
Hinsberger S, Hüsecken K, Groh M, Negri M, Haupenthal J, Hartmann RW. Discovery of Novel Bacterial RNA Polymerase Inhibitors: Pharmacophore-Based Virtual Screening and Hit Optimization. J Med Chem 2013; 56:8332-8. [DOI: 10.1021/jm400485e] [Citation(s) in RCA: 37] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- Stefan Hinsberger
- Helmholtz-Institute for Pharmaceutical
Research Saarland, Department
of Drug Design and Optimization, and ‡Pharmaceutical and Medicinal Chemistry, Saarland University, Campus C2.3, 66123 Saarbrücken, Germany
| | - Kristina Hüsecken
- Helmholtz-Institute for Pharmaceutical
Research Saarland, Department
of Drug Design and Optimization, and ‡Pharmaceutical and Medicinal Chemistry, Saarland University, Campus C2.3, 66123 Saarbrücken, Germany
| | - Matthias Groh
- Helmholtz-Institute for Pharmaceutical
Research Saarland, Department
of Drug Design and Optimization, and ‡Pharmaceutical and Medicinal Chemistry, Saarland University, Campus C2.3, 66123 Saarbrücken, Germany
| | - Matthias Negri
- Helmholtz-Institute for Pharmaceutical
Research Saarland, Department
of Drug Design and Optimization, and ‡Pharmaceutical and Medicinal Chemistry, Saarland University, Campus C2.3, 66123 Saarbrücken, Germany
| | - Jörg Haupenthal
- Helmholtz-Institute for Pharmaceutical
Research Saarland, Department
of Drug Design and Optimization, and ‡Pharmaceutical and Medicinal Chemistry, Saarland University, Campus C2.3, 66123 Saarbrücken, Germany
| | - Rolf W. Hartmann
- Helmholtz-Institute for Pharmaceutical
Research Saarland, Department
of Drug Design and Optimization, and ‡Pharmaceutical and Medicinal Chemistry, Saarland University, Campus C2.3, 66123 Saarbrücken, Germany
| |
Collapse
|
21
|
Osmon DR, Berbari EF, Berendt AR, Lew D, Zimmerli W, Steckelberg JM, Rao N, Hanssen A, Wilson WR. Reply to Eisen and Denholm, Dauchy et al, Fierer, and Nguyen and Jones. Clin Infect Dis 2013; 57:162-4. [PMID: 23537909 DOI: 10.1093/cid/cit189] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
22
|
Dey A, Chatterji D. Tracing the Variation in Physiological Response to Rifampicin Across the Microbial Spectrum. ACTA ACUST UNITED AC 2012. [DOI: 10.4167/jbv.2012.42.2.87] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Affiliation(s)
- Abhinav Dey
- Molecular Biophysics Unit, Indian Institute of Science, Bangalore, India
| | - Dipankar Chatterji
- Molecular Biophysics Unit, Indian Institute of Science, Bangalore, India
| |
Collapse
|
23
|
Chen LF, Kaye D. Current use for old antibacterial agents: polymyxins, rifamycins, and aminoglycosides. Med Clin North Am 2011; 95:819-42, viii-ix. [PMID: 21679793 DOI: 10.1016/j.mcna.2011.03.007] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
This article reviews three classes of antibacterial agents that are uncommonly used in bacterial infections and therefore can be thought of as special-use agents. The polymyxins are reserved for gram-negative bacilli that are resistant to virtually all other classes of drugs. Rifampin is used therapeutically, occasionally as a companion drug in treatment of refractory gram-positive coccal infections, especially those involving foreign bodies. Rifaximin is a new rifamycin that is a strict enteric antibiotic approved for treatment of traveler's diarrhea and is showing promise as a possible agent for refractory Clostridium difficile infections. The aminoglycosides are used mainly as companion drugs for the treatment of resistant gram-negative bacillary infections and for gram-positive coccal endocarditis.
Collapse
Affiliation(s)
- Luke F Chen
- Division of Infectious Diseases and International Health, Department of Medicine, Duke University Medical Center, Box 102359, Hanes House, Durham, NC 27710, USA.
| | | |
Collapse
|
24
|
Current use for old antibacterial agents: polymyxins, rifamycins, and aminoglycosides. Infect Dis Clin North Am 2010; 23:1053-75, x. [PMID: 19909897 DOI: 10.1016/j.idc.2009.06.004] [Citation(s) in RCA: 45] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
This article reviews three classes of antibacterial agents that are uncommonly used in bacterial infections and therefore can be thought of as special-use agents. The polymyxins are reserved for gram-negative bacilli that are resistant to virtually all other classes of drugs. Rifampin is used therapeutically, occasionally as a companion drug in treatment of refractory gram-positive coccal infections, especially those involving foreign bodies. Rifaximin is a new rifamycin that is a strict enteric antibiotic approved for treatment of traveler's diarrhea and is showing promise as a possible agent for refractory Clostridium difficile infections. The aminoglycosides are used mainly as companion drugs for the treatment of resistant gram-negative bacillary infections and for gram-positive coccal endocarditis.
Collapse
|
25
|
|
26
|
Tascini C, Ferranti S, Messina F, Menichetti F. In vitro and in vivo synergistic activity of colistin, rifampin, and amikacin against a multiresistant Pseudomonas aeruginosa isolate. Clin Microbiol Infect 2008. [DOI: 10.1111/j.1469-0691.2000.00169.x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
27
|
Rifampicin inhibits the retinal neovascularization in vitro and in vivo. Exp Eye Res 2008; 86:131-7. [DOI: 10.1016/j.exer.2007.10.003] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/25/2007] [Revised: 10/09/2007] [Accepted: 10/10/2007] [Indexed: 11/23/2022]
|
28
|
Javerliat I, Goëau-Brissonnière O, Bruneval P, Coggia M. Experimental Study of a New Vascular Graft Prebonded with Antibiotic: Healing, Toxicity, and Antibiotic Retention. Ann Vasc Surg 2007; 21:603-10. [PMID: 17823042 DOI: 10.1016/j.avsg.2007.06.005] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/24/2007] [Accepted: 06/26/2007] [Indexed: 11/16/2022]
Abstract
Despite refinements in surgical techniques, routine antibioprophylaxis, and anesthesiology, vascular prosthetic infections remain a serious complication of reconstructive vascular surgery. The purpose of this study was to evaluate the healing, the toxicity, and the antibiotic delivery of a new vascular graft, preloaded with rifampin and tobramycin. Sixteen dogs underwent infrarenal aortic bypass. They were divided into three groups. In test group 1 (n = 8), dogs received grafts loaded with a standard concentration of antibiotics. In test group 2 (n = 4), dogs received grafts loaded with twice the standard concentration of antibiotics. A control group (n = 4) received a commercial gelatin-sealed graft. Grafts were harvested after different periods of time and submitted to histological evaluation and antibiotic dose determination. Liver and kidney toxicities were evaluated from dosages performed on serum samples taken at different time periods between graft implantation and harvesting. The healing of antibiotic-loaded grafts was similar to that of commercial grafts, without any signs of toxicity. These results suggest resistance to infection of these prebonded grafts in an animal model.
Collapse
Affiliation(s)
- Isabelle Javerliat
- Department of Vascular Surgery, Ambroise Paré University Hospital, Assistance Publique-Hôpitaux de Paris, Boulogne-Billancourt, France
| | | | | | | |
Collapse
|
29
|
DuPont HL, Jiang ZD. Influence of rifaximin treatment on the susceptibility of intestinal Gram-negative flora and enterococci. Clin Microbiol Infect 2005; 10:1009-11. [PMID: 15522005 DOI: 10.1111/j.1469-0691.2004.00997.x] [Citation(s) in RCA: 75] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
The development of rifaximin- and rifampicin-resistant intestinal coliforms was studied in 27 subjects receiving rifaximin for 3 days by plating stool samples on media containing rifaximin 200 mg/L or rifampicin 64 mg/L before treatment (day 0), after treatment was completed (day 3), and after a further 2 days (day 5). The susceptibility of enterococci grown on day 0 and day 3 was also studied in 71 subjects. Significant increases in antimicrobial-resistant coliform flora were not seen in either the rifaximin-treated or the placebo-treated subjects. Enterococci recovered pre- and post-treatment showed similar susceptibilities. Rifaximin did not select for significant resistance in the Gram-negative and Gram-positive intestinal flora during therapy.
Collapse
Affiliation(s)
- H L DuPont
- University of Texas, Houston School of Public Health, Houston, TX 77030, USA.
| | | |
Collapse
|
30
|
Kaye D. Current use for old antibacterial agents: polymyxins, rifampin, and aminoglycosides. Infect Dis Clin North Am 2004; 18:669-89, x. [PMID: 15308281 DOI: 10.1016/j.idc.2004.04.007] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
Abstract
This article discusses three classes of antibacterial agents that are uncommonly used in bacterial infections (other than mycobacterial infections) and can be thought of as special-use agents. These are the polymyxins, rifampin, and the aminoglycosides.
Collapse
Affiliation(s)
- Donald Kaye
- Department of Medicine, Drexel University, College of Medicine, 3300 Henry Avenue, Philadelphia, PA 19129, USA.
| |
Collapse
|
31
|
Fernandez M, Rench MA, Albanyan EA, Edwards MS, Baker CJ. Failure of rifampin to eradicate group B streptococcal colonization in infants. Pediatr Infect Dis J 2001; 20:371-6. [PMID: 11332660 DOI: 10.1097/00006454-200104000-00002] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
BACKGROUND Mucous membrane colonization with group B streptococci (GBS) frequently persists in infants after treatment of invasive infection and may be associated with recurrent disease. OBJECTIVE To determine the frequency with which GBS colonization persists at mucous membrane sites after treatment of invasive early or late onset infection and to determine the efficacy of oral rifampin in eradicating colonization in these infants and their mothers. METHODS Cultures for isolation of GBS were obtained from infants and their mothers after completion of the infant's parenteral therapy, 1 week later when rifampin therapy was initiated and at approximately 1 and 4 weeks after completion of rifampin therapy. Rifampin was administered (10-mg/kg dose; maximum, 600 mg) twice daily for 4 days. RESULTS Ten of 21 infants (48%) and 13 (65%) of their 20 mothers were colonized with GBS at throat or rectal (infant) or vaginal, rectal or breast milk (mother) sites before rifampin was initiated. One week or less after rifampin treatment, 7 (70%) infants and 4 (31%) mothers remained colonized with GBS. At study completion 6 infants and 7 mothers had GBS colonization. Persistent colonization was not related to GBS serotype, to initial rifampin minimal inhibitory concentration or to the development of rifampin resistant strains. CONCLUSIONS Rifampin treatment for four days utilized as a single agent after completion of parenteral therapy failed to reliably eradicate GBS colonization in infants.
Collapse
Affiliation(s)
- M Fernandez
- Department of Pediatrics, Baylor College of Medicine, Houston, TX 77030, USA
| | | | | | | | | |
Collapse
|
32
|
Abstract
Understanding the breadth of systemic antimicrobial agents available for use by the dermatologist and their associated side-effect profiles and drug interactions allows the clinician to offer patients optimal care in the management of cutaneous infectious disease.
Collapse
Affiliation(s)
- N S Sadick
- Department of Dermatology, Weill Medical College of Cornell University, New York City, New York, USA
| |
Collapse
|
33
|
Tascini C, Ferranti S, Messina F, Menichetti F. In vitro and in vivo synergistic activity of colistin, rifampin, and amikacin against a multiresistant Pseudomonas aeruginosa isolate. Clin Microbiol Infect 2000; 6:690-1. [PMID: 11284934 DOI: 10.1046/j.1469-0691.2000.00169.x] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
|
34
|
Johansson A, Berglund L, Gothefors L, Sjöstedt A, Tärnvik A. Ciprofloxacin for treatment of tularemia in children. Pediatr Infect Dis J 2000; 19:449-53. [PMID: 10819342 DOI: 10.1097/00006454-200005000-00011] [Citation(s) in RCA: 59] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
BACKGROUND Children with tularemia are, irrespective of severity of disease, usually subjected to parenteral treatment with aminoglycosides. Based on available susceptibility testing, quinolones might be effective oral alternatives of parenteral therapy. These drugs cause arthropathy in immature animals, but this risk is currently regarded to be low in humans. PATIENTS AND METHODS In 12 patients (median age, 4 years; range, 1 to 10) with ulceroglandular tularemia, a 10- to 14-day course of oral ciprofloxacin, 15 to 20 mg/kg daily in 2 divided doses, was prescribed. Microbiologic investigations included identification of the infectious agent by PCR and culture of wound specimens, as well as determination of antibiotic susceptibility of isolates of Francisella tularensis. RESULTS Defervescence occurred within 4 days of institution of oral ciprofloxacin in all patients. After a median period of 4.5 days (range, 2 to 24), the patients were capable of outdoor activities. In 2 cases, treatment was withdrawn after 3 and 7 days because of rash. In both cases a second episode of fever occurred. All children recovered without complications. In 7 cases F. tularensis was successfully cultured from ulcer specimens and tested for susceptibility to ciprofloxacin. MIC values for all isolates were 0.03 mg/l. CONCLUSION In our sample of 12 patients ciprofloxacin was satisfactory for outpatient treatment of tularemia in children.
Collapse
Affiliation(s)
- A Johansson
- Department of Clinical Microbiology, Infectious Diseases, Umeå University, Sweden
| | | | | | | | | |
Collapse
|
35
|
Muñoz L, Martino R, Subirà M, Brunet S, Sureda A, Sierra J. Intensified prophylaxis of febrile neutropenia with ofloxacin plus rifampin during severe short-duration neutropenia in patients with lymphoma. Leuk Lymphoma 1999; 34:585-9. [PMID: 10492083 DOI: 10.3109/10428199909058487] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
To analyse the impact of intensified prophylaxis with ofloxacin plus rifampin (O+R) in neutropenic patients we used this combination in 40 consecutive cycles of ifosfamide, cytarabine, prednisolone and etoposide (IAPVP-16). This salvage chemotherapy regimen for lymphoma usually produces four to six days of severe neutropenia without significant extrahematologic toxicities. We compared the infectious morbidity during neutropenia under O+R with 58 consecutives cycles using either norfloxacin or no prophylaxis (control group). Fifty-three percent of control group patients and 20% of the O+R group developed febrile neutropenia that required hospital admission (p<0.001, 95% CI for the difference between both proportions of 16% to 51%). Bacteremia was documented in two patients in the O+R group and six in the control group (p=0.08). Gram-positive cocci (GPC) accounted for all six bacteremias in the control group, while both cases in O+R group were due to a quinolone-resistant gram-negative bacteria (GNB) (p<0.01 for GPC). Five patients (13%) who received O+R and 23 (40%) in control group developed fever of unknown origin, p<0.001, while the total duration of hospitalization due to febril neutropenia was 42 days and 158 days, respectively (p<0.001). In conclusion, intensified prophylaxis with O+R appears to reduce the rate of febrile neutropenia and GPC bacteremia in patients with short and severe neutropenia, which translates into a reduction in the need for hospitalization.
Collapse
Affiliation(s)
- L Muñoz
- Division of Clinical Hematology, Hospital De La Santa Creu i Sant Pau, Barcelona, Spain
| | | | | | | | | | | |
Collapse
|
36
|
Lovering AM, MacGowan AP. A comparative study of the rifampicin binding and elution characteristics for collagen- and albumin-sealed vascular grafts. Eur J Vasc Endovasc Surg 1999; 17:347-50. [PMID: 10204059 DOI: 10.1053/ejvs.1998.0785] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
OBJECTIVES To assess the rifampicin binding and elution characteristics for three protein-sealed vascular grafts. DESIGN In vitro study. MATERIALS Cardial and Hemashield collagen-sealed and the DeBakey/Vasculour albumin-sealed vascular grafts. METHODS The grafts were soaked in a 60,000 mg/l solution of rifampicin at 37 degrees C for 15 min. Bound drug was eluted from the grafts at 37 degrees C and at timed intervals the concentrations of rifampicin remaining in the grafts were determined. RESULTS Although all three grafts contained high concentrations of rifampicin immediately after soaking these rapidly fell on washing and only a small fraction of the adsorbed rifampicin was tightly bound to the grafts. Rifampicin loading of this tightly bound fraction was similar for the two collagen-sealed grafts (1.7-2.0 mg/kg) but higher for the albumin-sealed graft (16.0 mg/kg). Elution of the tightly bound fraction appeared to follow first-order kinetics with elimination half-lives of 89-141 h. The concentrations of rifampicin remaining in the grafts after eight days were above those needed to inhibit sensitive staphylococci and were 0.7 mg/kg (collagen-sealed grafts) to 3.7 mg/kg (albumin-sealed graft). CONCLUSIONS There is broad equivalence between the rifampicin binding and elution for the two collagen-sealed grafts, but there appears to be slightly higher binding for the albumin-sealed graft.
Collapse
Affiliation(s)
- A M Lovering
- Bristol Centre for Antimicrobial Research and Evaluation, Department of Medical Microbiology, Southmead Hospital, U.K
| | | |
Collapse
|
37
|
Mindermann T, Zimmerli W, Gratzl O. Rifampin concentrations in various compartments of the human brain: a novel method for determining drug levels in the cerebral extracellular space. Antimicrob Agents Chemother 1998; 42:2626-9. [PMID: 9756766 PMCID: PMC105908 DOI: 10.1128/aac.42.10.2626] [Citation(s) in RCA: 57] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Antimicrobial therapy for brain infections is notoriously difficult because of the limited extent of knowledge about drug penetration into the brain. Therefore, we determined the penetration of rifampin into various compartments of the human brain, including the cerebral extracellular space (CES). Patients undergoing craniotomy for resection of primary brain tumors were given a standard dose of 600 mg of rifampin intravenously before the operation. A microdialysis probe (10 by 0.5 mm) was inserted into the cortex distantly from the resection and was perfused with two different rifampin solutions. Rifampin concentrations in the CES were calculated by the no-net-flux method. Intraoperatively, samples were taken from brain tumor tissue, perifocal tissue, and normal brain tissue in the case of pole resections. Rifampin concentrations in the various samples were determined by using a bioassay with Sarcinea lutea. In the various compartments, rifampin concentrations were highest within tumors (1.37 +/- 1.34 microg/ml; n = 8), followed by the perifocal region (0.62 +/- 0.67 microg/ml; n = 8), the CES (0.32 +/- 0.11 microg/ml; n = 6), and normal brain tissue (0.29 +/- 0.15 microg/ml; n = 7). Rifampin concentrations in brain tumors do not adequately reflect concentrations in normal brain tissue or in the CES. Rifampin concentrations in the CES, as determined by microdialysis, are the most reproducible, and the least scattered, of the values for all compartments evaluated. Rifampin concentrations in all compartments exceed the MIC for staphylococci and streptococci. However, CES concentrations may be below the MICs for some mycobacterial strains.
Collapse
Affiliation(s)
- T Mindermann
- Neurological Surgery, University Hospitals Basel, 4031 Basel, Switzerland.
| | | | | |
Collapse
|
38
|
Epstein ME, Amodio-Groton M, Sadick NS. Antimicrobial agents for the dermatologist. II. Macrolides, fluoroquinolones, rifamycins, tetracyclines, trimethoprim-sulfamethoxazole, and clindamycin. J Am Acad Dermatol 1997. [DOI: 10.1016/s0190-9622(18)30730-8] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/16/2022]
|
39
|
Epstein ME, Amodio-Groton M, Sadick NS. Antimicrobial agents for the dermatologist. II. Macrolides, fluoroquinolones, rifamycins, tetracyclines, trimethoprim-sulfamethoxazole, and clindamycin. J Am Acad Dermatol 1997; 37:365-81; quiz 382-4. [PMID: 9308549 DOI: 10.1016/s0190-9622(97)70135-x] [Citation(s) in RCA: 33] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
This article is the second of a two-part series reviewing antimicrobial agents that are used by the dermatologist. In part I we reviewed beta-lactam antibiotics and related compounds. In this section we again emphasize some newer agents (macrolides, fluoroquinolones) as well as some of the more commonly employed older agents (rifamycins, tetracyclines, trimethoprim-sulfamethoxazole, and clindamycin.
Collapse
Affiliation(s)
- M E Epstein
- Department of Medicine, North Shore University Hospital, Manhasset, New York, USA
| | | | | |
Collapse
|
40
|
|
41
|
Barber PG, Goldman WM, Avicolli AJS, Smith R, Rairden N, Maragni O, Chirico J, Mangone C. Antitubercular drugs. Tuberculosis (Edinb) 1995. [DOI: 10.1007/978-1-4899-2869-6_11] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
42
|
Archer GL, Climo MW. Antimicrobial susceptibility of coagulase-negative staphylococci. Antimicrob Agents Chemother 1994; 38:2231-7. [PMID: 7840550 PMCID: PMC284723 DOI: 10.1128/aac.38.10.2231] [Citation(s) in RCA: 125] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023] Open
Affiliation(s)
- G L Archer
- Department of Medicine, Medical College of Virginia, Virginia Commonwealth University, Richmond 23298-0049
| | | |
Collapse
|
43
|
Magnan PE, Seyral P, Raoult D, Branchereau A. In vitro antistaphylococcal activity of collagen-sealed Dacron vascular prostheses bonded with rifampin, vancomycin, or amikacin. Ann Vasc Surg 1994; 8:243-7. [PMID: 8043357 DOI: 10.1007/bf02018171] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
The goals of this study were to evaluate the in vitro antistaphylococcal activity of vascular Dacron prostheses to which a type I collagen and an antibiotic had been bonded. Collagen was fixed to the prosthesis either by an original grafting procedure or by impregnation. The antibiotics used included rifampin, vancomycin, and amikacin. They were bonded to the prosthesis either at the same time as the collagen or by soaking the prosthesis in an antibiotic solution at the beginning of the experiment. Each prosthesis was sliced into 6 mm diameter circles and preserved in a solution of saline and albumin, which was changed every day. Three disks were retrieved from each prosthesis at the beginning of the experiment and then every 24 hours; these were placed in gelose smeared with Staphylococcus aureus. The diameter of the inhibition area of each disk was measured at 24 hours. The initial inhibition area (So), the time at which the inhibition area was equal to 50% of So, and the time at which the activity was nil were used to characterize the activity of the prostheses and to calculate a beta coefficient of decreasing activity. The prostheses bonded with vancomycin or amikacin did not show adequate activity. Those bonded with rifampin were effective for at least 4 days. When rifampin was grafted to the prosthesis, the So was 278.6 mm2, 50% of So was reached within 10.4 days, the duration of effective activity was 25.7 days, and the beta coefficient was 0.067. The two prostheses soaked in rifampin had a significantly more rapid decrease (beta = 0.19 and 0.56) and a shorter duration of effective activity (12.4 and 4.5 days). Both collagen-coated prostheses, whether impregnated or soaked with rifampin, have a sufficient duration of activity to be tested in an animal model.
Collapse
Affiliation(s)
- P E Magnan
- Service de Chirurgie Vasculaire, Hôpital Sainte Marguerite, Marseille, France
| | | | | | | |
Collapse
|
44
|
Goëau-Brissonnière O, Leport C, Bacourt F, Lebrault C, Comte R, Pechère JC. Prevention of vascular graft infection by rifampin bonding to a gelatin-sealed Dacron graft. Ann Vasc Surg 1991; 5:408-12. [PMID: 1835641 DOI: 10.1007/bf02133043] [Citation(s) in RCA: 68] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
This study examines the efficacy of rifampin bonding to a gelatin-sealed knitted Dacron graft to prevent perioperative bacteremic vascular graft infection. Antibiotic bonding was obtained by soaking grafts for 15 minutes in a 1 mg/ml saline solution of rifampin at 37 degrees C. Nineteen dogs had thoracoabdominal aortic bypass: seven (group I) received a rifampin treated graft; six (group II) received an untreated gelatin-coated graft; and six (group III) received an uncoated Dacron graft. Two days later bacteremic challenge was produced by rapid intravenous injection of 5 x 10(5) colony forming units of methicillin resistant Staphylococcus aureus. Grafts were harvested five days after this challenge and cut into 10 fragments, each submitted to bacterial counts. Results were expressed as CFU/cm2 of graft material. In group I, no graft was infected, whereas all grafts in groups II and III were infected (p less than 0.05). Median bacterial counts from the infected fragments (median +/- SD) were similar in groups II (2.5 x 10(5) CFU/cm2) and III (4 x 10(4) CFU/cm2). Blood cultures at time of sacrifice were negative in all dogs in group I and positive in five of six dogs in groups II and III. Cultures of liver, spleen, kidney, and lung specimens were always negative in group I and positive in 22 of 24 specimens in group II and 23 of 24 specimens in group III. Soaking a gelatin-sealed Dacron graft in rifampin solution evidently prevents early bacteremic graft infection and secondary foci of infection in this model.
Collapse
|
45
|
Zimmerman SW, Ahrens E, Johnson CA, Craig W, Leggett J, O'Brien M, Oxton L, Roecker EB, Engeseth S. Randomized controlled trial of prophylactic rifampin for peritoneal dialysis-related infections. Am J Kidney Dis 1991; 18:225-31. [PMID: 1867179 DOI: 10.1016/s0272-6386(12)80883-3] [Citation(s) in RCA: 102] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
Staphylococcal infections are a major cause of catheter infections and peritonitis in peritoneal dialysis patients. Since catheter-related infections are associated with nasal carriage of Staphylococcus aureus in this population, we studied the effect of intermittent rifampin, an antibiotic known to decrease S aureus nasal carriage, on catheter-related infections and peritonitis. We randomly assigned 64 patients to receive either rifampin 300 mg twice daily for 5 days every 3 months or no treatment. The rifampin-treated patients had a significant delay in time to first catheter-related infection (P less than 0.015) and significantly fewer catheter-related infections overall (P less than 0.001). The catheter-related infection rate in rifampin-treated patients was .26 per patient-year versus .93 per patient-year in untreated patients. Multivariate analysis defined baseline colonization of nares or catheter exit-site and prior renal transplant as risk factors for catheter-related infections. There was no significant difference in peritonitis rates between groups, although the trend was for a delayed time to first episodes and fewer episodes in rifampin-treated patients. Adverse effects necessitated withdrawal of rifampin in four patients. We conclude that intermittent rifampin administration is effective in decreasing catheter-related infections in a peritoneal dialysis population.
Collapse
Affiliation(s)
- S W Zimmerman
- Department of Medicine, University of Wisconsin School of Medicine, Madison
| | | | | | | | | | | | | | | | | |
Collapse
|
46
|
Edelstein PH. Rifampin resistance of Legionella pneumophila is not increased during therapy for experimental Legionnaires disease: study of rifampin resistance using a guinea pig model of Legionnaires disease. Antimicrob Agents Chemother 1991; 35:5-9. [PMID: 2014980 PMCID: PMC244932 DOI: 10.1128/aac.35.1.5] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022] Open
Abstract
Isolates of Legionella pneumophila serogroup 1, obtained from guinea pigs with experimentally induced Legionnaires disease, were tested for rifampin resistance. Thirteen isolates were from animals treated with rifampin alone, four isolates were from animals treated with saline, and three isolates each were from animals treated with erythromycin or erythromycin plus rifampin; all of these isolates were derived from the same parent strain, F889. Most of the isolates were obtained from rifampin-treated animals that survived infection but had persistence of bacteria in their lungs at necropsy. No differences in rifampin agar dilution MICs were detected for the 23 isolates and parent strain that were tested. None of the 13 isolates from animals treated with rifampin alone had a high number of resistant organisms detected by using a rifampin gradient plate assay. Thirteen isolates plus the parent strain were tested by using a quantitative method of determining resistance frequency. Considerable heterogeneity among isolates was observed, but there was no evidence of increased resistance for any treatment group. The range of rifampin resistance frequencies was 10(-7) to 10(-8). No evidence for rifampin-induced resistance of L. pneumophila was found in this study.
Collapse
Affiliation(s)
- P H Edelstein
- Department of Pathology, University of Pennsylvania School of Medicine, Philadelphia 19104-4283
| |
Collapse
|
47
|
Nahata MC, Fan-Havard P, Barson WJ, Bartkowski HM, Kosnik EJ. Pharmacokinetics, cerebrospinal fluid concentration, and safety of intravenous rifampin in pediatric patients undergoing shunt placements. Eur J Clin Pharmacol 1990; 38:515-7. [PMID: 2379538 DOI: 10.1007/bf02336694] [Citation(s) in RCA: 23] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
The objectives of this study were to characterize the pharmacokinetics and determine the cerebrospinal fluid concentrations and safety of intravenous rifampin in pediatric patients undergoing shunt placement. Nine patients (mean age 5.6 y) received a single dose of rifampin, 20 mg.kg-1, administered intravenously 1 h prior to surgery. The peak serum concentrations ranged from 13.5-26.7 micrograms.ml-1; cerebrospinal fluid concentrations ranged from 0.12-3.0 (mean: 1.4) micrograms.ml-1. The mean total clearance, apparent distribution volume, and elimination half-life were 0.29 l.kg-1.h-1, 1.11.kg-1, and 2.8 h. The concentrations of rifampin achieved in the cerebrospinal fluid exceeded the minimum inhibitory concentrations by 100- to 1000-fold against Staphylococcus epidermidis. However, 5 of 9 patients developed cutaneous reactions during intravenous rifampin prophylactic therapy. Because of the high frequency of adverse effects and more than adequate rifampin concentrations achieved in the cerebrospinal fluid, rifampin doses lower than that used in this study may be evaluated in future studies.
Collapse
Affiliation(s)
- M C Nahata
- College of Pharmacy, Ohio State University, Department of Pediatrics, Columbus
| | | | | | | | | |
Collapse
|
48
|
Abstract
Infectious complications currently account for 80 percent of deaths from acute pancreatitis. The adjunctive role of antibiotics in the prevention and treatment of secondary pancreatic infections has received insufficient attention. Randomized clinical studies of effective antibiotics for prophylaxis or empiric therapy of pancreatic infections do not currently exist. In their absence, it is not known whether prophylactic antibiotics are useful in patients with acute pancreatitis. Until such studies are available, if antibiotics are to be used, their choice must be based upon indirect criteria: the ability of the antibiotic to effectively penetrate pancreatic tissue and juice, knowledge of the most common pancreatic pathogens, and the ability of the antibiotic to exceed the in vitro concentration (MIC-90) in pancreatic juice for the common pathogens. Recognition of the limited state of knowledge regarding antibiotics in acute pancreatitis may stimulate future investigations.
Collapse
Affiliation(s)
- E L Bradley
- Department of Surgery, Emory University School of Medicine, Atlanta, Georgia
| |
Collapse
|
49
|
Korting HC, Lukacs A. [Multi-step increase in resistance of Neisseria gonorrhoeae isolates after repeated in-vitro subinhibitory concentrations of second-generation quinolones]. Infection 1989; 17 Suppl 1:S6-10. [PMID: 2509374 DOI: 10.1007/bf01643626] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
Five recent gonococcal isolates were exposed to subinhibitory concentrations of several antibiotics in vitro 25 times. In the presence of rifampicin all strains quickly became resistant. In the presence of penicillin, enoxacin and ciprofloxacin, antimicrobial susceptibility also decreased. Here development of resistance, however, corresponded to the multi- and not to the one-step type. It seems remarkable that even at the end of the experiments no strain grew at concentrations of ciprofloxacin exceeding 0.064 mg/l. In conclusion, quick development of resistance need not be expected after the introduction of newer quinolones into the therapy of gonorrhoea on a large scale.
Collapse
Affiliation(s)
- H C Korting
- Dermatologische Klinik und Poliklinik, Ludwig-Maximilians-Universität München
| | | |
Collapse
|
50
|
Sweeney RW, Divers TJ, Benson C, Collatos C. Pharmacokinetics of rifampin in calves and adult sheep. J Vet Pharmacol Ther 1988; 11:413-6. [PMID: 3210270 DOI: 10.1111/j.1365-2885.1988.tb00204.x] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Affiliation(s)
- R W Sweeney
- Department of Clinical Studies, University of Pennsylvania School of Veterinary Medicine, Kennett Sq
| | | | | | | |
Collapse
|